German Registry for Transcatheter Tricuspid Valve Interventions

All-cause death and heart failure hospitalisation 1 year after transcatheter tricuspid valve treatment (TTVT)

Long-term all-cause death and heart failure hospitalisation after transcatheter tricuspid valve treatment (TTVT)

Short-term all-cause death and heart failure hospitalisation after transcatheter tricuspid valve treatment (TTVT)

Assessed by echocardiography, tricuspid regurgitation graded on a 4-grade scale.

Assessment for cardiopulmonal symptoms include edema scaling

NYHA classification I, II, III or IV

Assessed by standardized protocol testing 6-minute walking distance

Quality of life is assessed by standardized questionnaires including the Minnesota Living with Heart Failure Questionnaire

N-terminal pro Brain Natriuretic Peptide (NT-proBNP) in pg/ml

Procedural success is defined as a reduction of the tricuspid regurgitation to at least grade 2+ achieved by interventional treatment

The saftety outcome contains all complications which occur between the interventional treatment of the tricuspid regurgitation and discharge from the hospital. Data collection includes: mortality with differentiation of cardiac death and non-cardiac death, unplanned cardiac surgery, re-intervention of tricuspid valve, pericardial tamponade, intervention of coronary arteries. Moreover major adverse events as defined by MVARC2 criteria are recorded at discharge from hospital: death with differentiation of cardiac death and non-cardiac death, peri-procedural or spontaneous myocardial infarction, stroke, transient ischemic attack, life-threatening, major or minor bleeding, acute kidney failure, complications of the vascular access.